ut-logo website  
Register and login to access premium content
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

Home

ZYTIGA:

1. Treatment of Castration Resistant Prostate Cancer
... Targets for treating mCRPC The FDA approved abiraterone acetate (ZYTIGA, Janssen Biotech, Horsham, PA) in April 2010 for the treatment of patients with mCRPC who have received prior docetaxel chemotherapy. ...
2. Treatment of mCRCP
... should be taken into consideration during treatment selection. Targeted Therapies-Angiogenesis Targets The FDA approved abiraterone acetate (Zytiga, Janssen Biotech, Horsham, PA) in April 2010 for ...
3. Successful treatment of advanced metastatic prostate cancer following chemotherapy based on molecular profiling, "Beyond the Abstract," by Charles E. Myers, MD
BERKELEY, CA (UroToday.com) - In a case described in our recently published paper, we were faced with choosing the best treatment for a patient with prostate cancer who had progressed through radical prostatectomy, ...
4. AUA 2013 - Slide Presentation: ZYTIGA® (abiraterone acetate): Introducing a new option for patients with mCRPC before chemotherapy
SAN DIEGO, CA USA (UroToday.com) - Presented at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA